Skip to content

First to See the Light

Menu
  • About
  • Our Legacy
  • Network
  • News
  • Connect
Menu
  • About
  • Our Legacy
  • Network
  • News
  • Connect

News & Insights

Business Development: What it Means for Your Business

A Message from Spencer Trask CEO, Bill Clifford: Respect the Individual Employee as Never Before

Bouncing Back from COVID-19: How Lessons Learned from Past Public Crises May Be Applied to the Challenges of Today

There is No Post-COVID-19 Culture

Staying Alive Post Pandemic

Did COVID Disrupt Your Exit Plan? Here’s How to Get Back on Track

Interos Protects Supply Chains with the Trensant AI Platform

Interos: SolarWinds Attack Highlights Need for Supply Chain Paradigm Shift

The MSC: Regeneration Orchestrator

The Affordable Care Act: Twelve Years Later

Supply Chain Unicorn Built on Spencer Trask & Co. AI Venture

ST Announces Global Crowdsourcing Program for Polio Eradication

ST Backed Ultra Capital Draws New Capital

ST Supports 6th Annual World Polio Day

Firm Funded by ST Acquired by Circle

Trensant AI Acquired by Interos Solutions

ST and Affiliates Close Sale of ImThera

Chairman Gives Talk on Smartphone Origin

Spencer Trask - Our Legacy

ST Chairman at Mobile World Congress

DLF to Honor Spencer Trask & CO. Chairman

ST Recognizes 100 Year Anniversary

What’s your bright idea?

1 (800) 622 -7078

ideas@spencertraskco.com

Linkedin Twitter
Contact Us

Immune Response Corporation

Pioneering the vaccine revolution

Developing new vaccines to fight AIDS and cancer

The first FDA-approved cancer vaccine, an immune therapy made from the patient’s own cells.

Polio vaccine hero Dr. Jonas Salk and our Chairman founded The Immune Response Corporation. They recruited the team, attracted $350 million from investors and corporate partners, and developed groundbreaking immune therapies.

IRC technology was key to the first FDA-approved cancer vaccine, sipuleucel-T. More than 40,000 patients have received this prostate cancer therapy, which appears to be more effective in African American men, with a 48% percent reduction in death, compared to white men. The first cell-based immunotherapy, this approval opened the floodgates for immunotherapeutics, today the largest category of pharmaceuticals.